Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

Who owns Neuphoria Therapeutics Inc.?

Ticker: NEUP
CUSIP Number: 64136e102

Tip: Access positions for across all investors

Analyze quarterly positions in Neuphoria Therapeutics with up to 7 years of data, all consolidated into one spreadsheet

Download as csv

Download as Excel

Top investors of Neuphoria Therapeutics stock

Who bought or sold Neuphoria Therapeutics Inc. this quarter?

Fund or Company Name	Shares Held	Valued At	Change in Shares	As Of	Actions
Lynx1 Capital Management	875k	$3.6M	0%	Mar 2026	View chart
AdvisorShares Investments	155k	$632k	16%	Mar 2026	View chart
Shay Capital	151k	$615k	100%	Mar 2026	View chart
Balyasny Asset Management	142k	$579k	100%	Mar 2026	View chart
Squadron Capital Management	77k	$312k	100%	Mar 2026	View chart
Geode Capital Management	52k	$212k	201%	Mar 2026	View chart
Diadema Partners	50k	$194k	133%	Dec 2025	View chart
Ikarian Capital	47k	$193k	0%	Mar 2026	View chart
Vanguard Fiduciary Trust	34k	$137k	100%	Mar 2026	View chart
ADAR1 Capital Management	30k	$122k	0%	Mar 2026	View chart
FNY Investment Advisers	27k	$107k	0%	Mar 2026	View chart
Vanguard Group	21k	$81k	0%	Dec 2025	View chart
Citadel Advisors	19k	$79k	100%	Mar 2026	View chart
Bridgeway Capital Management	15k	$57k	100%	Dec 2025	View chart
Boothbay Fund Management	14k	$57k	0%	Mar 2026	View chart
XTX Topco	12k	$47k	100%	Dec 2025	View chart
Commonwealth Equity Services	11k	$46k	0%	Mar 2026	View chart
Merck & Co	10k	$41k	0%	Mar 2026	View chart
UBS Group	2.3k	$9.4k	40%	Mar 2026	View chart
Tower Research Capital	1.4k	$5.4k	241%	Dec 2025	View chart
Rhumbline Advisers	202.00	$821.998600	0%	Mar 2026	View chart
Morgan Stanley	58.00	$232.000000	0%	Mar 2026	View chart

Who sold out of Neuphoria Therapeutics?

Fund or Company Name	Date Sold	Shares Held	Valued At
None	Dec 2025	169k	$656k
Prosperity Wealth Management	Sep 2025	30k	$352k
Jane Street	Dec 2025	17k	$64k
Persistent Asset Partners	Dec 2025	13k	$52k

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z